You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Researchers profiled T cells in the cerebrospinal fluid of healthy individuals and multiple sclerosis patients using single-cell RNA-seq and T cell receptor sequencing.
In PNAS this week: epigenetic study of Kaposi's sarcoma-associated herpesvirus, non-coding variant prioritization tool, and more.
Based in Boston with operations in Ireland and Iceland, the reorganized company is supporting COVID-19 testing and population genomics as it sheds its China division.
The collaborators hope to establish new models of human disease using patient-derived stem cells, with support from Bloomberg Philanthropies.
The results of the study, which involved more than 47,000 MS patients and 68,000 unaffected controls, explain almost half of the disease's estimated heritability.
Using brain samples from individuals with or without multiple sclerosis, researchers detected declining projection neuron levels and related immune cell shifts.
In PLOS this week: genes and pathways linked to multiple sclerosis, Salmonella enterica diversity in reptiles, and more.
In PNAS this week: study of epigenetic patterns in mammalian eggs, clonal expansion patterns in CD8+ T cells, and more.
The researchers plan to analyze clinical records and genetic data from whole-exome sequencing for more than 3,000 patients using DNAnexus' Apollo platform.
In PLOS this week: map of breakpoints in individuals with complex chromosomal rearrangements, sequence of virus that infects African armyworm, and more.
The head of Operation Warp Speed tells Bloomberg he expects the paused AstraZeneca and Johnson & Johnson vaccine trials to resume soon.
A new UK government says socioeconomic factors, not genetics, account for disparities in deaths due to COVID-19 between ethnic groups, the Financial Times reports.
NPR reports on an Alzheimer's disease drug trial that is continuing despite the pandemic.
In Nature this week: CRISPR-Cas3 system for making large deletions efficiently, more.